摘要
Objective:To review the latest progress on the pathogenic mechanism and management of rheumatoid arthritis(RA)-associated coronary artery disease(CAD),and propose advice on future management optimization as well as prospects for research and development of new therapeutic regimen.Data sources:This study was based on data obtained from PubMed up to May 2019 using various search terms and their combinations,including coronary artery disease,myocardial ischemia,cardiovascular diseases,RA,rheumatic diseases,treatment,therapy,strategies,immunotherapy,inflammation,and anti-inflammation.Study selection:All retrieved literature was scrutinized,most relevant articles about the pathogenic mechanism and clinical management,especially anti-inflammatory therapy of RA-associated CAD were reviewed.Results:RA is an immune-mediated chronic inflammatory disease which has a great social disease burden.In addition to typical arthritic manifestations,RA also affects extra-articular tissues and organs,within which the involvement of the cardiovascular system,especially incorporating CAD,is the leading cause of death for patients with RA.Recently,numerous basic and clinical studies have been carried out on the mechanism of CAD development and progression under the inflammatory cascade of RA.The effect of traditional RA drugs on CAD risk management has been gradually clarified,and more emerging biologic agents are being explored and studied,which have also achieved satisfactory outcomes.Furthermore,with the success of the CANTOS clinical trial,novel anti-inflammatory therapy for the prevention of cardiovascular disease is believed to have a broad prospect.Conclusions:RA is an independent risk factor for CAD,which mainly results from the underlying inflammatory cascade;therefore,anti-inflammatory therapy,especially the emerging novel biologic drugs,is important for CAD management in patients with RA and may also be a promising approach among the general population.
基金
This work was supported by the National Key R&D Program of China(2016YFC0901500 and 2016YFC0901502
2017YFC0907601 and 2017YFC0907604)
CAMS Innovation Fund for Medical Sciences(CIFMS)(2016-I2M-1-002).
